Of the patients, 57.6%, 50.0% and 37.3% were oestrogen receptor (ER) positive, progesterone receptor (PR) positive and HER2 positive, respectively, and 16.7% of them were diagnosed with triple-negative breast cancer. Here, ERBB2 is linked to triple-negative breast carcinoma.